Biomarkers in ocular chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Authors: Wang Chunmiao,  Zhang Qi
DOI: 10.3760/cma.j.cn115989-20190121-00025
Published 2022-05-10
Cite asChin J Exp Ophthalmol, 2022, 40(5): 470-474.

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a common treatment for hematological malignant and non-malignant diseases.However, dry eye, ocular chronic graft-versus-host disease (cGVHD) and other common ocular complications related to cGVHD after allo-HSCT, can seriously affect the quality of life of patients, and may lead to corneal perforation or even blindness in severe cases.With the constant development of allo-HSCT, the incidence of cGVHD-related dry eye is on the rise with the increasing number of patients and the prolonged survival time after transplantation.The pathogenesis, diagnosis and treatment for the disease still remain poorly understood and studied.Biomarkers are of importance for the early prevention, diagnosis and active treatment of cGVHD-related dry eye at present.Progress of biomarkers for cGVHD-related dry eye after HSCT including lacrimal glands, cornea and conjunctiva, meibomian glands, tears and the peripheral blood were reviewed.

Key words:

Dry eye syndromes; Biomarkers; Hematopoietic stem cell transplantation; Chronic graft versus host disease

Contributor Information

Wang Chunmiao

Department of Ophthalmology, the First Affiliated Hospital of Chongqing Medical University, Chongqing Key Lab of Ophthalmology, Chongqing Eye Institute, Chongqing 400016, China

Zhang Qi

Department of Ophthalmology, the First Affiliated Hospital of Chongqing Medical University, Chongqing Key Lab of Ophthalmology, Chongqing Eye Institute, Chongqing 400016, China

(Read 8 times, 1 visits today)